Inhibition of Co-Crystallization of Olmesartan Medoxomil and Hydrochlorothiazide for Enhanced Dissolution Rate in Their Fixed Dose Combination
Olmesartan medoxomil (Olm) and hydrochlorothiazide (HCTZ) are fixed dose combination (FDC) for treatment of hypertension. They have hydrogen bonding sites and may interact during co-processing. The consequences of such interaction are not clear. This study investigated the possibility of this interaction during co-processing. The research was extended to inhibit deleterious interactions. The drugs were co-evaporated from ethanolic solution to maximize the chance of interaction. This was performed in the absence and presence of hydroxypropyl methylcellulose (HPMC) and/or aerosil. The products were characterized using Fourier transform infrared spectroscopy (FTIR), differential thermal analysis, and powder X-ray diffraction (PXRD) in addition to dissolution studies. Co-evaporation of Olm with HCTZ in the absence of excipients produced crystalline material with FTIR spectrum showing intermolecular hydrogen bonding. This material showed thermal pattern of new crystalline species. This was identified as Olm/HCTZ co-crystal by PXRD. This co-crystallization reduced the dissolution rate of both drugs. This co-crystallization was inhibited in the presence of HPMC, but the dissolution rate was not significantly enhanced accordingly. Co-processing in the presence of both HPMC and aerosil eliminated the co-crystallization and minimized the intermolecular drug-drug interaction with subsequent dissolution enhancement. The study introduced a composition for fixed dose combination of Olm and HCTZ with enhanced dissolution.
KEY WORDSco-amorphous co-evaporates fixed dose combination olmesartan dissolution hydrochlorothiazide dissolution
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Compliance with Ethical Standards
Conflict of Interest
The authors declare no conflict of interest.
- 3.Jayalakshmi J, Palanisamy P, Gomathi J. Comparison of polymers in enhancing the dissolution rate of olmesartan medoxomil by solid dispersion technique using solvent evaporation method. Am J PharmTech Res. 2017;7:289–301.Google Scholar
- 8.Sathali AA, Jayalakshmi J. Enhancement of solubility and dissolution rate of olmesartan medoxomil by solid dispersion technique. J Curr Chem Pharm Sci. 2013;3:123–34.Google Scholar
- 10.Kamble R, Palve P, Mehta P. Preparation and evaluation of amorphous olmesartan medoxomil with porous silica microparticles using spray-drying technique. J Adv Pharm Technol Res. 2014;4:444–50.Google Scholar
- 14.El Maghraby GM, El Gohary AY, Osman MA. Enhancement of dissolution rate of hydrochlorothiazide. Int J Pharm Pharm Sci. 2016;8:427–33.Google Scholar
- 18.Validation of analytical procedures: methodology. ICH Harmonized Tripartite Guideline. 1996.Google Scholar
- 20.Gera S, Cheruvu S, Zakkula A, Sampathi S. Synthesis and evaluation of olmesartan medoxomil complex with SBE7 β-cd for enhanced dissolution and bioavailability. Int J Pharm Pharm Sci. 2016;8:333–43.Google Scholar
- 23.Rus LM, Tomuta I, Iuga C, Maier C, Kasco I, Borodi G, et al. Compatibility studies of indapamide/pharmaceutical excipients used in tablet preformulation. Farmacia (Bucharest Rom). 2012;60:92–101.Google Scholar
- 24.Tile MK, Pawar AY. Solubility and dissolution rate enhancement of olmesartan medoxomil by chitosan base co-crystal approach. Int J Pharm Biol Sci. 2015;5:400–11.Google Scholar
- 26.Mali RK, Pawar HA, Mali KK, Dias RJ. Fast disintegrating tablets of olmesartan medoxomil using solid dispersion technique. Asian J. Pharm. 2017;11:425–33.Google Scholar
- 34.Qi MH, Chen WS, Zhou H, Chen JY, Ren GB. Solution-mediated polymorphic transformation of amorphous form to form I of olmesartan medoxomil in methanol-water mixture solvents. Cryst Res Technol. 2017;52. https://doi.org/10.1002/crat.201700038.
- 35.Sangeetha E, Rao VU, Sudhakar M, Manisha S. Enhancement of solubility and bioavailability of hydrochlorthiazide using solid dispersion technique. Am J Adv Drug Delivery. 2015;3:308–16.Google Scholar